- Protocol Short Name and Number: Myeloma Vaccine, 1401
- Protocol Long Name: A Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
- BMT CTN # 1401 Co-Chair: David Avigan MD
- BMT CTN # 1401 Co-Chair: Nina Shah, MD
- BMT CTN # 1401 Co-Chair: David Chung, MD
- BMT CTN # 1401 Protocol Officer: Marcelo Pasquini, MD
- BMT CTN # 1401 Protocol Coordinator: Nicole Ritzau, RN; bmtctn1401@emmes.com
- Keywords: Vaccine, Vaccination, Lenalidomide, Maintenance, Multiple Myeloma, MM, Dendritic Cell, Auto Transplant, Autologous Transplant, Auto